Status:

COMPLETED

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study

Lead Sponsor:

Innovo Therapeutics, Inc.

Conditions:

Healthy Volunteer

Eligibility:

All Genders

19-55 years

Phase:

PHASE1

Brief Summary

This is a 2-part study. Parts 1 and 2 will be a randomized, double-blind, placebo-controlled investigations of SAD (Part 1) and MAD (Part 2) of orally administered INV-101 in healthy adult subjects. F...

Eligibility Criteria

Inclusion

  • Male subjects must follow protocol specified contraception guidance as described in Section 7.4.5 and agree to refrain from sperm donation until 90 days after the last dosing.
  • Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing based on subject self-reporting.
  • Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit.
  • Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, or vital signs, as deemed by the PI or designee at the screening visit, including the following:

Exclusion

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  • History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
  • History or presence of hypersensitivity or idiosyncratic reaction to compounds related to the study drug or study drug excipients.

Key Trial Info

Start Date :

April 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 13 2024

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT06938204

Start Date

April 1 2024

End Date

September 13 2024

Last Update

April 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Pharmaron

Baltimore, Maryland, United States, 02451